Well, news was kind of things that we already knew. The only difference is the payroll elimination announced that nobody expected.
It is showing a great dose of good corporate business sense and it showes that they do believe in their new drug. But at the same time company is now kind of a ghost one.
This is now more speculative than ever: meeting with fda about a phase 3 has probably a 50 50 chance of approval but not enough money to do it all by themselves.
This would probably means more financing coming and more dilution.
So after review, SSS will stay on my speculative play for the year and as usual whenever profit is made on those spec play, you take the money anad run.
Never forget rule #1 NEVER INVEST MORE THAN WHAT YOU CAN AFFORD TO LOSE.
Aucun commentaire:
Publier un commentaire